SCHEMBL346450

SCHEMBL346450

NC(CCC(=O)NC(CSCO)C(=O)NCC(=O)O)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.70
GSTK1 Q9Y2Q3 1/20 0.70
GLO1 Q04760 4/20 0.61
NOD1 Q9Y239 5/20 0.43
FOLH1 Q04609 2/20 0.41
GRM8 O00222 1/20 0.40
GRM6 O15303 1/20 0.40
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GSR P00390 1/20 0.40
CYP1A2 P05177 1/20 0.40
GRIK1 P39086 1/20 0.40
GRM5 P41594 1/20 0.40
GRIA1 P42261 1/20 0.40
GRIA2 P42262 1/20 0.40
GRIA3 P42263 1/20 0.40
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40
SLC1A1 P43005 1/20 0.40
GRIA4 P48058 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21067395 1.00 PTGS1 (0.70) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL346451 1.00 PTGS1 (0.70) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL17433875 0.92 PTGS1 (0.70) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL29449890 0.92 PTGS1 (0.70) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL2898626 0.91 PTGS1 (0.65) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL11867151 0.91 PTGS1 (0.65) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL7081152 0.91 PTGS1 (0.68) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL7081151 0.91 PTGS1 (0.68) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL4158582 0.91 PTGS1 (0.68) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL4158575 0.91 PTGS1 (0.68) PTGS1GSTK1GLO1NOD1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
WO-2024204791-A1 METHOD FOR PRODUCING METHYL COMPOUND 三菱ケミカル株式会社 2024-10-03 WO claimed
US-20240011058-A1 CANNABIDIOLIC ACID (CBDA) SYNTHASE VARIANTS, AND MANUFACTURE AND USE THEREOF TEEWINOT LIFE SCIENCES CORP (US) 2024-01-11 US claimed
US-20230407239-A1 TETRAHYDROCANNABINOLIC ACID (THCA) SYNTHASE VARIANTS, AND MANUFACTURE AND USE THEREOF TEEWINOT LIFE SCIENCES CORP (US) 2023-12-21 US claimed
US-11753663-B2 Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing adipate, 6-aminocaproate, hexamethylenediamine or caprolactam related thereto GENOMATICA, INC. (US) 2023-09-12 US claimed
US-11535874-B2 Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing succinate related thereto GENOMATICA, INC. (US) 2022-12-27 US claimed
CN-115521880-A Methanol-free culture method of methylotrophic yeast for biosynthesis of value-added products 生物促进及生物合成咨询有限公司 2022-12-27 CN claimed
WO-2022103950-A1 CANNABIDIOLIC ACID (CBDA) SYNTHASE VARIANTS, AND MANUFACTURE AND USE THEREOF TEEWINOT LIFE SCIENCES CORPORATION (US) 2022-05-19 WO claimed
WO-2022103938-A1 TETRAHYDROCANNABINOLIC ACID (THCA) SYNTHASE VARIANTS, AND MANUFACTURE AND USE THEREOF TEEWINOT LIFE SCIENCES CORPORATION (US) 2022-05-19 WO claimed
US-20210032632-A1 MATERIALS AND METHODS FOR THE BIOSYNTHESIS OF SEVEN CARBON CHEMICALS IN THE PRESENCE OF METHANOL OXIDATION INV NYLON CHEMICALS AMERICAS, LLC 2021-02-04 US claimed
WO-2018022613-A1 MATERIALS AND METHODS FOR THE BIOSYNTHESIS OF SEVEN CARBON CHEMICALS IN THE PRESENCE OF METHANOL OXIDATION INVISTA TEXTILES (U.K.) LIMITED (GB) 2018-02-01 WO claimed
US-20180023088-A1 MATERIALS AND METHODS FOR THE BIOSYNTHESIS OF SEVEN CARBON CHEMICALS IN THE PRESENCE OF METHANOL OXIDATION INVISTA North America S.à.r.l 2018-01-25 US claimed
US-20260130873-A1 COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA AND OTHER CONDITIONS THE REGENTS OF THE UNIV OF COLORADO A BODY CORPORATE (US) 2026-05-14 US disclosed
US-12529078-B2 Microorganisms and methods for improving product yields on methanol using acetyl-CoA synthesis GENOMATICA, INC. (US) 2026-01-20 US disclosed
US-20250388910-A1 METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL AGAIN BIO APS (DK) 2025-12-25 US disclosed
US-12465579-B2 Compositions and methods for treating homocystinuria and other conditions THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2025-11-11 US disclosed
US-20020128205-A1 Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors DUKE UNIVERSITY OFFICE OF SCIENCE AND TECHNOLOGY (US) 2002-09-12 US disclosed
US-20020119507-A1 Determination method of biological component and reagent kit used therefor TOYO BOSEKI KABUSHIKI KAISHA (JP) 2002-08-29 US disclosed
WO-2002055018-A2 INHIBITING GS-FDH TO MODULATE NO BIOACTIVITY DUKE UNIVERSITY (US) 2002-07-18 WO disclosed
EP-1213358-A2 Method and kit for the determination of a biological component Toyo Boseki Kabushiki Kaisha (JP) 2002-06-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12529078-B2 Microorganisms and methods for improving product yields on methanol using acetyl-CoA synthesis ALDOA, FDPS, DERA PTGS1 1671/4885GSTK1 998/4885GLO1 258/4885
US-20260130873-A1 COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA AND OTHER CONDITIONS SLC6A12, CTH, SLC6A6 PTGS1 2904/4885GSTK1 1188/4885GLO1 81/4885
US-20250388910-A1 METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL ADH5, ADH1C, ADH1A PTGS1 1485/4885GSTK1 1371/4885GLO1 343/4885
US-20020128205-A1 Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors GGH, GSS, GSR PTGS1 18/4885GSTK1 53/4885GLO1 91/4885
US-11535874-B2 Microorganisms and methods for enhancing the availability of reducing equivalents in the presence of methanol, and for producing succinate related thereto ME3, ME2, ME1 PTGS1 526/4885GSTK1 775/4885GLO1 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.